Cost-Effectiveness Analysis of Tdap in the Prevention of Pertussis in the Elderly

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  McGarry, Lisa J ^a   Krishnarajah, Girishanthy ^b   Hill, Gregory ^a   Skornicki, Michelle ^a   Pruttivarasin, Narin ^a   Masseria, Cristina ^b   Arondekar, Bhakti ^b   Pelton, Stephen I ^c   Weinstein, Milton C ^a,d  

^a OPTUM   (United States)

^b GLAXOSMITHKLINE   (United States)

^c BOSTON UNIVERSITY   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE;

ARTICLE; COHORT ANALYSIS; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DEATH; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; ELDERLY CARE; HEALTH CARE COST; HEALTH ECONOMICS; HOSPITAL COST; INCIDENCE; PERTUSSIS; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; TREATMENT OUTCOME;

AGED; COHORT STUDIES; COST-BENEFIT ANALYSIS; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; HUMANS; WHOOPING COUGH;

EID: 84883350471     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067260     Document Type: Article

References (37)

1. Centers for Disease Control and Prevention (2006) Preventing Tetanus, Diphtheria, and Pertussis Among Adolescents: Use of Tetanus Toxoid, reduced Diphtheria Toxoid and Acellular Pertussis Vaccine: recommendations of the Advisory Committee on immunization Practices (ACIP). MMWR 55 (No. RR-17): 1-44.
2. Centers for Disease Control and Prevention (2011) Surveillance & Reporting. Trends. Available: http://www.cdc.gov/pertussis/surv-reporting.html. Accessed 2011 Jul 21.
3. Centers for Disease Control and Prevention (2011) Pertussis: Summary of Vaccine Recommendations. Available: http://www.cdc.gov/vaccines/vpd-vac/pertussis/recs-summary.htm. Accessed 2011 Jul 21.
4. Centers for Disease Control and Prevention (2010) Updated Recommendations for Use of Tetanus Toxoid, reduced Diphtheria Toxoid and Acellular Pertussis Vaccine from the Advisory Committee on Immunization Practices. MMWR 60(01); 13-15.
5. Cortese MM, Baughman AL, Brown K, Srivastava P, (2007) A "new age" in pertussis prevention new opportunities through adult vaccination. Am J Prev Med 32(3): 177-185.
6. de Melker HE, Versteegh FG, Schellekens JF, Teunis PF, Kretzschmar M, (2006) The incidence of Bordetella pertussis infections estimated in the population from a combination of serological surveys. J Infect 53(2): 106-13.
7. Grenfell B, (2011) Boosting understanding of pertussis outbreaks. Proc Natl Acad Sci U S A 108(18): 7279-7280.
8. Centers for Disease Control and Prevention (2012) ACIP Provisional Tdap Recommendations. Available: http://www.cdc.gov/vaccines/recs/provisional/Tdap-feb2012.htm. Accessed 2012 Mar 25.
9. Gold MR, Siegel JE, Russell LB, Weinstein M (1996) Cost-effectiveness in health and medicine. New York: Oxford University Press. 176-213 p.
10. Arias E, (2010) 2006 US Life Tables. Natl Vital Stat Rep 58(21): 1-40.
11. Centers for Disease Control and Prevention (2012) Advisory Committee on Immunization Practices Summary Report, February 22-23, 2012, Atlanta, Georgia. Available: http://www.cdc.gov/vaccines/recs/acip/downloads/min-feb12.pdf. Accessed 2012 June 4.
12. California Department of Public Health (2011) Pertussis Report. Figure 5, Pertussis rates by age. Available: http://www.cdph.ca.gov/programs/immunize/Documents/PertussisReport20119.pdf.
13. Washington State Department of Health (2012) Weekly pertussis update for Washington State 2012 year to date (YTD) confirmed and probable cases reported through 6/23/2012 (week 25). Available: http://www.doh.wa.gov/Portals/1/Documents/Pubs/348-254-PertussisUpdate.pdf.
14. Lee GM, Murphy TV, Lett S, Cortese MM, Kretsinger K, et al. (2007) Cost effectiveness of pertussis vaccination in adults. Am J Prev Med 32(3): 186-193.
15. Schmitt HJ, von König CH, Neiss A, Bogaerts H, Bock HL, et al. (1996) Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA Jan 3 275(1): 37-41.
16. De Vries R, Kretzschmar M, Schellekens JF, Versteegh FG, Westra TA, et al. (2010) Cost-effectiveness of adolescent pertussis vaccination for the Netherlands: using an individual-based dynamic model. PLoS One. 5(10): e13392.
17. Caro JJ, Getsios D, El-Hadi W, Payne K, O'Brien JA (2005) Pertussis immunization of adolescents in the United States: an economic evaluation. Pediatr Infect Dis J 24(5 Suppl): S75-82.
18. Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, et al. (2007) The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 25(27): 5086-5096.
19. Wells CD, Murrill WB, Arguedas MR, (2004) Comparison of health-related quality of life preferences between physicians and cirrhotic patients: implications for cost-utility analyses in chronic liver disease. Dig Dis Sci 49(3): 453-458.
20. Hanmer J, Lawrence WF, Anderson JP, Kaplan RM, Fryback DG, (2006) Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. Med Decis Making 26(4): 391-400.
21. Centers for Disease Control and Prevention (2010) Vaccine Price List. Available: http://www.cdc.gov/vaccines/programs/vfc/downloads/archived-pricelists/2010/12162010.htm#adult. Accessed 2010 Dec 20.
22. U.S. Census Bureau (2009) American Community Survey. Available: http://www.census.gov/acs/www/data_documentation/data_main/. Accessed 2010 Dec 20.
23. Bureau of Labor Statistics (2011) Consumer Price Index. Available: http://data.bls.gov/cgi-bin/srgate. Series ID: CUUR0000SAM. Accessed 2011 Jul 21.
24. PDR Network LLC (2010) Red Book: Pharmacy's Fundamental Reference, 2010 edition. Montvale, NJ: Thomson Reuters (Healthcare) Inc.
25. McDowell MA, Fryar CD, Ogden CL, (2009) Anthropometric reference data for children and adults: United States, 1988-1994. Vital Health Stat 11. 249: 1-68.
26. MAG Mutual Healthcare Solutions (2009) Physician's Fee and Coding Guide 2010.
27. Lee LH, Pichichero ME, (2000) Costs of illness due to Bordetella pertussis in families. Arch Fam Med 9(10): 989-996.
28. O'Brien JA, Caro JJ, (2005) Hospitalization for pertussis: profiles and case costs by age. BMC Infect Dis 5: 57.
29. US Bureau of Labor Statistics (2011) Current Population Survey 2010. Available: http://www.bls.gov/cps/cpsaat3.pdf. Accessed 2011 May 16.
30. US Bureau of Labor Statistics (2011) Employment, Hours, and Earnings from the Current Employment Statistics survey (National). Available: http://www.census.gov/hhes/www/cpstables/032010/perinc/toc.htm. Accessed 2011 May 16.
31. Lee GM, Lett S, Schauer S, LeBaron C, Murphy TV, et al. (2004) Societal costs and morbidity of pertussis in adolescents and adults. Clin Infect Dis 39(11): 1572-1580.
32. Meltzer D, (1997) Accounting for future costs in medical cost-effectiveness analysis. JHE 16 (1): 33-64.
33. Smith KJ, Wateska AR, Nowalk MP, Raymund M, Nuorti JP, et al. (2012) Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine JAMA. 307(8): 804-812 doi:10.1001/jama.2012.169.
34. Pellissier JM, Brisson M, Levin MJ (2007) Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine Nov 28; 25(49): 8326-37. Epub 2007 Oct 17.
35. The Advisory Committee on Immunization Practices (ACIP) (2008) The ACIP Ad Hoc WG on Economic Analyses Guidance for health economics studies presented to the ACIP. Available: http://www.cdc.gov/vaccines/acip/committee/guidance/economic-studies.html. Accessed 2013 May 5.
36. Alemayehu B, Warner KE, (2004) The lifetime distribution of health care costs. Health Serv Res June 39(3): 627-642.
37. U.S. Bureau of Labor Statistics (2011) Consumer Expenditure Survey, 2010 Average annual expenditures and characteristics. Available: http://www.bls.gov/cex/#data. Accessed 2013 May 5.